BACKGROUND & AIMS There are few validated biomarkers that can be used to predict outcomes for patients with colorectal cancer. Part of the challenge is the genetic and molecular heterogeneity of colorectal tumors not only among patients, but also within tumors. We have explored intratumor heterogeneity at the epigenetic level, due to its dynamic nature. We analyzed DNA methylation profiles of t...

Clinicopathological evidence is accumulating that a superficial-type (flat) colorectal tumor is a distinct neoplastic entity. To clarify the genetic characteristics of this tumor, we investigated the K-ras gene mutations and morphological features of 43 tumors of this type. A mutation of the K-ras codon 12 was detected in only 5 (16%) of 31 adenomas and 2 (17%) of 12 adenocarcinomas. The presen...

Objective(s): Ten-eleven translocation (TET) family members have been shown to be involved in the development of many tumors. However, the biological role of the TET family and its mechanism of action in colorectal carcinogenesis and progression remain poorly understood. Materials and Methods:We measured the expression levels of TET family members in colorectal cancer (CRC) specimens, in the c...

The treatment of metastatic colorectal cancer (mCRC) remains one of the largest hurdles in cancer therapeutics to date. The most advanced treatment option for mCRC patients are anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) that bind to and inhibit the activity of EGFR. While the use of anti-EGFR mABs has had great impact in the treatment of mCRC, it has now been wide...

The ability to tailor biologic therapy based on the status of tumor biomarkers and monoclonal antibodies has become very important in the last years. The role of tumor biomarkers in treating colorectal cancer, specifically the K-RAS gene, was identified. K-RAS had a higher interest after Lievre and colleagues reported at the 2008 American Society of Clinical Oncology (ASCO) meeting, their analy...

n engl j med 367;17 nejm.org october 25, 2012 1651 in this study. Indeed, only 66 patients with mutated-PIK3CA tumors used aspirin after a diagnosis of colorectal cancer and only 3 of them died of colorectal cancer during the follow-up period. Assuming these findings are confirmed in large prospective studies, one may predict that the PIK3CA mutation status of colorectal tumors will become a us...

Smoking has been consistently associated with an increased risk of colorectal adenomas and hyperplastic polyps as well as colorectal cancer. Conversely, nonsteroidal anti-inflammatory drugs (NSAID) have been associated with reduced colorectal cancer risk. We conducted a population-based case-control study to evaluate the joint association between smoking and regular NSAID use with colorectal ca...

BACKGROUND Colorectal carcinoid tumors are often described as being low-grade malignant. The objective of the current study was to address the clinicopathological features and outcomes of patients with colorectal carcinoid tumors. METHODS A total of 63 patients with colorectal carcinoid tumors were identified and evaluated using surgical pathology files and medical records between January 200...

In article number 2200044, Weiping Wang and co-workers developed a H2S-responsive nanocarrier based on the self-assembly of trigonal small molecules. Hydrophobic drugs, such as doxorubicin, can be encapsulated precisely released in H2S-enriched colorectal tumors for effective cancer therapy.

Abstract An antitumor abscopal effect is occasionally observed in radiotherapy and plasma treatment. It a remote induced by tumor irradiation that delays the growth of other distant, nonirradiated tumors. In this study, it was demonstrated normal tissues (not tumors) also leads to an effect. When pulsed streamer discharge irradiated left flanks mice where no existed, murine colorectal carcinoma...